Results 1 to 10 of about 29,284 (247)

Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Efficacy and safety of ibrutinib 560 mg once daily or placebo combined with bendamustine and rituximab (BR) were assessed in patients with mantle cell lymphoma in a randomized phase 3 study (SHINE).
Per Olsson Gisleskog, Belén Valenzuela, Nicoline Treijtel, Sanjay Deshpande, Todd Henninger, Juan José Perez‐Ruixo   +5 more
doaj   +2 more sources

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae

Frontiers in Pharmacology, 2021
Ibrutinib is an orally bioavailable, irreversible selective Bruton’s tyrosine kinase inhibitor that has demonstrated impressive therapeutic effects in patients with B cell malignancies.
Kun Wang, Qiushi Xu, Hanbing Zhong
doaj   +1 more source

Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy

Haematologica, 2021
Ibrutinib is highly active and produces long-term responses in patients with Waldenström macroglobulinemia (WM), but acquired resistance can occur with prolonged treatment.
Joshua N. Gustine, Shayna Sarosiek, Catherine A. Flynn, Kirsten Meid, Carly Leventoff, Timothy White, Maria Luisa Guerrera, Lian Xu, Amanda Kofides, Nicholas Tsakmaklis, Manit Munshi, Maria Demos, Christopher J. Patterson, Xia Liu, Guang Yang, Zachary R. Hunter, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo   +18 more
doaj   +1 more source

Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS

Molecules, 2023
Ibrutinib, orelabrutinib, and zanubrutinib are all Bruton’s tyrosine kinase inhibitors, which have greatly improved the treatment of B-cell malignancies. In this study, an LC-MS/MS method was developed and validated for the determination of orelabrutinib,
Lu-Ning Sun, Yang Zhao, Zhou-Yi Qian, Xiang-Long Chen, Hong Ma, Yu-Jiao Guo, Hao Shen, Yong-Qing Wang   +7 more
doaj   +1 more source

Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry

Pathology and Oncology Research, 2022
Background: Ibrutinib is widely known as an effective and well-tolerated therapeutical choice of the chronic lymphocytic leukaemia (CLL). However, acquired resistance may occur during the treatment, causing relapse.
Ferenc Takács, Ferenc Takács, Lili Kotmayer, Ágnes Czeti, Gábor Szalóki, Tamás László, Gábor Mikala, Ágnes Márk, András Masszi, Péter Farkas, Márk Plander, Júlia Weisinger, Judit Demeter, Sándor Fekete, László Szerafin, Beáta Margit Deák, Erika Szaleczky, Adrienn Sulák, Zita Borbényi, Gábor Barna   +19 more
doaj   +1 more source

Ibrutinib-related uveitis: A case series

American Journal of Ophthalmology Case Reports, 2022
Purpose: Four cases of ibrutinib-related uveitis are presented, which are to the best of our knowledge the first in the literature. Possible mechanisms of ibrutinib-mediated uveitis are explored.
Zelia K. Chiu, Jonathan KS. Goh, Cecilia Ling, Ming-Lee Lin, Anthony J. Hall   +4 more
doaj   +1 more source

Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus

Haematologica, 2020
The Bruton tyrosine kinase inhibitor ibrutinib has become a leading therapy against chronic lymphoid leukemia. Recently, ibrutinib has been associated with the occurrence of invasive fungal infections, in particular invasive aspergillosis. The mechanisms
Damien Blez, Marion Blaize, Carole Soussain, Alexandre Boissonnas, Aïda Meghraoui-Kheddar, Natacha Menezes, Anaïs Portalier, Christophe Combadière, Véronique Leblond, David Ghez, Arnaud Fekkar   +10 more
doaj   +1 more source

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study

Cancer Medicine, 2022
Background Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib‐based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real‐world efficacy
Yuchen Zhang, Panpan Liu, Jun Cai, Hongmei Jing, Liqun Zou, Huiqiang Huang, Yuanbin Wu, Wenyu Li, Liye Zhong, Xueli Jin, Xu Ye, Ru Feng, Huilai Zhang, Liling Zhang, Lie Lin, Xiuhua Sun, Yuyang Tian, Zhongjun Xia, Zhiming Li, He Huang, Yi Xia, Qingqing Cai   +21 more
doaj   +1 more source

Ibrutinib is not an effective drug in primografts of TCF3-PBX1

Translational Oncology, 2020
Aim: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients with multiple myeloma, non-Hodgkin lymphoma and chronic lymphoblastic leukemia. We previously showed that primary cells of children with TCF3-PBX1 positive B-
Cesca van de Ven, Aurélie Boeree, Femke Stalpers, C. Michel Zwaan, Monique L. Den Boer   +4 more
doaj   +1 more source

CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma

Cell Death Discovery, 2022
Altered features of tumor cells acquired across therapy can result in the survival of treatment-resistant clones that may cause minimal residual disease (MRD).
Viktoria Fuhr, Shanice Heidenreich, Mugdha Srivastava, Angela Riedel, Johannes Düll, Elena Gerhard-Hartmann, Andreas Rosenwald, Hilka Rauert-Wunderlich   +7 more
doaj   +1 more source